MATRIX Penny Stocks

[JAKE17]

Jan 06, 2005 (M2 PRESSWIRE via COMTEX) -- The Emerging Stock Report begins
coverage today on a very interesting and dynamic company that astute investors
should take note of. MultiCell Technologies, Inc., (OTCBB: MUCL), is a leading
provider of liver cell-based products for drug discovery and therapeutic
applications. MultiCell has leveraged its proprietary cell technologies to
engineer liver cell lines that retain their native functionality, continuously
regenerate, and are non-tumorigenic. This could also lead potentially to
development of adult stem cells. This means that MultiCell's cell lines may save
years of time and millions of dollars during preclinical drug discovery,
development and testing stages because the cell lines can be used instead of
animal or human testing.

In addition to selling hepatocytes to the pharmaceutical industry, it is
developing cell-based toxicological and drug screening tests.

Xenogenics Corporation, a majority-owned subsidiary, is a developmental stage
enterprise that owns all of the rights to the Sybiol(r) Bio-synthetic liver
device for which a patent is pending in 15 countries, including the United
States.

Predicting how a drug will behave in humans before clinical testing requires
sophisticated in vitro tests to complement in vivo tests. Early drug metabolism
models can help predict drug-drug interactions and help prioritize compound
selection for further development.

Drug induced liver injury is now the leading cause of liver failure in the U.S.

As drug recalls occur, and labor and animal costs rise, affordable early
screening is demanded.

MultiCell's immortalized human hepatocyte lines closely resemble primary human
liver cells in morphology and function. Hepatocytes express drug-metabolizing
enzymes that biotransform drugs or substances ingested into the body, so they
help predict the effect of a compound on human livers. MultiCell's cell lines
are sensitive to compounds that increase the expression of CYP3A4, an essential
feature of in vitro model systems when studying drug-drug interactions. They
eliminate the problem of limited supply and organ donor variability that
restrict the use of harvested human liver cells for enzyme induction, cellular
toxicity assays and other in vitro screening. The Emerging Stock Report feels
that The Company and their technology represent a very effective way to reduce
the tremendous costs in related drug testing and also hold promise in a range of
other areas. The Emerging Stock Report will continue to monitor the industry and
companies who are having an impact and report to astute investors.